

Immunotherapy perspectives in the new era of B-cell editing

Natsuko Ueda, Marine Cahen, Yannic Danger, Jérôme Moreaux, Christophe Sirac, Michel Cogné

► To cite this version:

Natsuko Ueda, Marine Cahen, Yannic Danger, Jérôme Moreaux, Christophe Sirac, et al.. Immunotherapy perspectives in the new era of B-cell editing. Blood Advances, 2021, 5 (6), pp.1770-1779. 10.1182/bloodadvances.2020003792 . hal-03202338

HAL Id: hal-03202338 https://univ-rennes.hal.science/hal-03202338

Submitted on 19 Apr 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1	
2	Immunotherapy perspectives in the new era of B-cell editing
3	Running title: Engineered B cells for therapy?
4 5	Ueda Natsuko ^{1*} , Cahen Marine ^{2*} , Danger Yannic ¹ , Moreaux Jérôme ³ , Sirac Christophe ² & Cogné Michel ^{1, 2}
6	¹ INSERM U1236, University of Rennes 1, Etablissement Français du Sang, Rennes, France.
7	² INSERM U1262, CNRS UMR 7276, Limoges University, Limoges, France.
8	³ CNRS UMR 9002, Institute of Human Genetics, Montpellier, France.
9	[*] Both authors contributed equally to this work
10	
11	
12	Correspondence: michel.cogne@inserm.fr
13	
14	

15 Abstract:

Since the early days of vaccination, targeted immunotherapy has gone through multiple conceptual 16 17 changes and challenges. It now provides the most efficient and up-to-date strategies for either preventing 18 or treating infections and cancer. Its most recent and successful weapons are autologous T cells carrying 19 chimeric antigen receptors, engineered purposely for binding cancer-specific antigens and therefore used 20 for so-called adoptive immunotherapy. We now face the merger of such achievements in cell therapy: 21 using lymphocytes redirected on purpose to bind specific antigens and the clustered regularly interspaced 22 short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) revolution, which conferred 23 genome-editing methodologies with both safety and efficacy. This unique affiliation will soon and 24 considerably expand the scope of diseases susceptible to adoptive immunotherapy and of immune cells 25 available for being reshaped as therapeutic tools, including B cells. Following the monumental success 26 story of passive immunotherapy with monoclonal antibodies (mAbs), we are thus entering into a new era, 27 where a combination of gene therapy/cell therapy will enable reprogramming of the patient's immune system and notably endow his B cells with the ability to produce therapeutic mAbs on their own. 28

29 1. Introduction

30

31 Various strategies are currently available for passive immunotherapy, notably with monoclonal antibodies 32 (mAbs) mimicking endogenous immunoglobulins for targeting an antigen (Ag), and thus well tolerated. 33 Active immunotherapy is, on the contrary, based on the patient's own immune system, as after 34 vaccination. Finally, adoptive immunotherapy reshapes autologous Ag-specific cells on purpose and is 35 now to be boosted by new genetic engineering methods. Although future chimeric antigen receptors 36 (CAR) T-cell protocols will likely replace lentiviral expression by clustered regularly interspaced short 37 palindromic repeats (CRISPR)-mediated retailoring of T-cell receptor (TCR) genes, gene editing could 38 also be applied to other cell lineages, especially B cells.

39

B cells provide the best suited immunoglobulin factory for producing either membrane-bound or secreted
 immunoglobulin in lymphocytes or plasma cells (PCs). In lymphocytes, membrane immunoglobulin
 provides the Ag-binding component of the B-cell receptor, which, on Ag sensing and presentation,
 triggers immunoglobulin class switching and affinity maturation before activated cells differentiate into
 immunoglobulin-secreting PCs.

45

46 The modular architecture of immunoglobulin was synthetically remodeled under multiple formats: single-47 chain (sc) fragments, minibodies, bi-specific Abs, and immunotoxins. Gene engineering methodologies 48 now make it doable to express such retailored immunoglobulin in primary B cells, the in vivo use of 49 which might then address multiple unmet health needs. Endogenously synthesized mAbs would notably 50 be valuable in situations needing either (1) lifelong treatment (autoimmune, inflammatory, infectious, 51 genetic, or residual cancer diseases), (2) permanent infusion (circumventing the issues of 52 pharmacodynamic variations seen with intravenous injection and of rapid in vivo catabolism seen with bi-53 and trispecific mAbs), (3) local delivery in sites where PCs are homing, and/or (4) efficient expression 54 despite unfit structure (for mAbs affected by chemistry, manufacturing, and control issues because of 55 nonoptimal structures).

56

57 This review provides an overview of such recent promising advances for adoptive immunotherapy.

- 58
- 59 60

61 2. Immunotherapy from the origins

62 63

Active immunotherapy began centuries ago with variolation to immunize people against smallpox and led to the concept of vaccination with viruses closely related to a pathogen but attenuated or non-pathogenic (**Figure 1**). Many vaccines now consist of purified or synthetic microbial components or simply nucleic acids encoding them. Recombinant viruses also provide platforms for developing new vaccines against emerging pathogens such as the recently arisen SARS-CoV-2.

69

Passive immunotherapy reached an initial milestone with a Nobel Prize in Medicine (1901), awarded to Behring for serotherapy of diphtheria, based on the administration of serum from convalescent patients. Besides infections, anti-rhesus D immunoglobulin G (IgG) from immunized donors are also widely administrated to mothers after delivery to prevent alloimmunization. Finally, passive immunotherapy strategies now include a huge array of recombinant mAbs targeting tumor or microbial Ag for specifically treating multiple disorders.

76

77 Cytokines can also be used to modulate immune responses, and inversely, mAbs are available for 78 counteracting the action of tumor necrosis factor α or interleukin-6 (IL-6) in inflammatory conditions, 79 notably those resulting from adoptive immunotherapy.

80

Cell therapy began in the 1950s for treating leukemia with bone marrow transplantation, which became safer after the discovery of the human leukocyte antigen system. Such allogenic transplants often associate with graft-versus-host disease, which can now be controlled and used for its graft-versus-tumor effects.

85

86 Cancer therapy can also make use of autologous tumor-infiltrating lymphocytes¹, which notably proved

efficient for treating melanomas. Recently, it became possible to engineer T cells expressing chimeric antigen receptors (CAR-T-cells)², and use of immune cells generated from induced pluripotent stem cells 89 also emerged^{3,4}. Although such therapies become a new standard, using other lineages could expand the

90 spectrum of immunotherapies, and B cells are specifically attractive in this regard, given their capacities

91 to produce large amounts of immunoglobulin and to support immune memory.

92 3. Recent developments in immunotherapy

93

Although antibodies and immune cells are the most specific tools for immunotherapy, new strategies for
 manipulating their production are further expanding the spectrum of their applications (Figure 2).

96 97

98 A. Recent developments of mAb-therapy99

100 mAbs provide the largest class of biomedicines for treating cancers, infections, and autoimmunity, and 101 their efficacy constantly improves. Murine mAbs have been largely replaced by less immunogenic 102 chimeric, humanized, or even entirely human mAbs. Abs can be conjugated with cytotoxic drugs and 103 with other functional proteins for conveying them to specific targets. The improved targeting of antibody-104 drug conjugates translates into lower toxicity of the attached drug. Antibody-drug conjugate specificity 105 can even be increased by making use of bispecific mAbs. Strategies for enhancing mAb stability are also 106 available either through optimized binding to the neonatal Fc receptor (FcRn) or through conjugation with 107 hydrophilic polymers such as polyethylene glycol. Reciprocally, a classical strategy to extend the half-life 108 of recombinant proteins and eventually strengthen their immunomodulating properties is to fuse them 109 with an IgG Fc domain that notably results in their recycling by the FcRn. Etanercept, a soluble tumor 110 necrosis factor receptor (TNFR)-Fc; abatacept, a soluble cytotoxic T-lymphocyte-associated protein 4 111 (CTLA4)-Fc; and luspatercept (activinRIIb-Fc) are such immunomodulatory fusion proteins.

112

There are still some limitations with mAb therapy, such as the treatment escape or the formation of 113 aggregates⁵, and we thus need next-generation strategies delivering Abs with modulated half-life, effector 114 properties, biodistribution, and toxicity. This also includes functional Ab fragments, monovalent Fabs or 115 bivalent F(ab')₂, single-domain Abs (nanobodies), and single-chain variable fragments (ScFv). 116 Nanobodies composed of VL, VH, or V_HH (ie, the type of V domain naturally found in some sc camelid 117 118 Abs) are small-size molecules that remain as specific as conventional Abs. They are highly soluble, do 119 not aggregate, and efficiently reach poorly vascularized tissues, and, in the absence of effector domains, 120 they mostly act as antagonists or allosteric inhibitors⁶.

121

122 ScFvs are composed of linked VH and VL domains, eventually combined as dimers (diabody), trimers 123 (tribody), or even tetramers (tetrabody), to increase their avidity for the target. Associating different 124 ScFvs can cumulate their specificities, as for bispecific T-cell engagers (BiTEs) aimed at bridging target with effector cells. Blinatumomab, for example, bridges CD19⁺ target cells with cytotoxic T cells, and a 125 126 trispecific Ab was proposed to target myeloma cells together with CD3 on T cells and the costimulatory 127 CD28⁷. Similarly, natural killer cell engagers (NKCEs) associate anti-CD16 binding NK cells, with 1 128 (BiKE) or 2 (TriKE) other scFvs specific for cancer cells. Some TriKEs additionally bind a cytokine, 129 enhancing NK activity⁸. Instead of 3 Fabs, another format of NKCEs includes an Fc domain, naturally 130 binding CD16, together with an anti-NKG2A checkpoint inhibitor Fab further increasing NK activity by blocking the NKG2A/MHC class I inhibitory signal⁹. Being smaller than regular mAbs, such next-131 132 generation Abs can reach a broader biodistribution¹⁰.

133

Multivalent Abs are also attractive next-generation weapons against pathogens and notably brought broad
 anti-HIV specificity and protection in a nonhuman primate (NHP) model¹¹.

136 137

138 B. Current stage of cell therapy with retargeted T cells (CAR T cells)

139
140 CAR T cell therapy is the latest success story in cell therapy. It is based on the forced expression of a new
141 Ag-binding receptor able to activate transduced or transfected primary T cells against a given Ag (usually
142 a tumor Ag)¹². Additional modifications of engineered T cells were also proposed to ensure local
143 secretion by T cell of a soluble anticancer molecule, using CAR T cells as micro-pharmacies¹³.

144

As for CAR T cells tisagenlecleucel (Kymriah; Novartis) and axicabtagene ciloleucel (Yescarta; Gilead), approved in 2017 against CD19, current CAR T cells mostly rely on retroviruses and lentiviruses.

147 Although there is no report of oncogenic insertion in the case of CAR T cells, such vectors still carry this

potential risk, calling for the development of safer gene delivery strategies. Electroporation is a common mean for introducing naked DNA, RNA, or proteins into cells, and CAR T cells were indeed also obtained after simple plasmid electroporation but only with transient expression^{14,15}. DNA insertion and stable expression with rarer oncogenic integration than with retroviruses were also obtained using transposase-based systems^{16,17}.

152

DNA mini-circles (devoid of bacterial DNA) are also efficient vectors and have yielded functional CAR
 T cells persisting in vivo for more than 28 days¹⁸. They, however, still carry a risk of random genomic
 insertion.

157

Electroporation of mRNA provides an alternative to DNA and can yield expression greater than 90%, with 80% cell viability¹⁹. Although restricted to transient (<1 week) expression, this is hereby attractive in terms of safety, with no risk of oncogenic integration and obviating the need for any suicide safety system for eliminating transfected cells in case of side effects²⁰. It, however, remains to be demonstrated whether such transient CAR expression would yield cancer remission²¹.

163

Although simple electroporation of nucleic acids is costly in terms of cell viability, use of nanoparticles captured through endocytosis was recently used for improving CAR T-cell transfection²². This strategy could also be applied for mRNA transfection²³. Altogether, CAR T-cell therapy still carries limitations related to efficiency, persistence of engineered T cells, safety, and pricing. Future protocols resolving these limitations and notably including precise genome edition will crucially help to broaden their applications.

170 171

172

C. Cell therapy in the era of precise genome editing

Although random genomic insertion carries safety issues, new genome editing tools now make it possible
to induce on-purpose mutations, deletions, and insertions. These tools, especially the CRISPR/Cas9
system and its variants, are entering into therapeutic applications at least based on their ex vivo use^{24,25}.
Precise genome edition thus begins to be developed for safer generation of CAR T cells by targeting the
TCR loci, simultaneously disrupting endogenous TCR expression and bringing expression of a specific
CAR.

- 180
- 181 182

a. Recent developments of gene editing tools

183 After zinc finger nucleases and transcription activator-like effector nucleases first provided DNA scissors and were efficiently used for TCR gene edition²⁶⁻²⁸, CRISPR/Cas9 has become the most efficient and 184 versatile system for genome engineering via RNA-guided cleavage²⁹. The CRISPR/Cas9 toolbox now 185 uses single guide RNA molecules, combining both RNA molecules necessary for initiating a specific 186 cleavage³⁰, and the Cas9 nuclease delivered to cells by DNA or mRNA transfection or simply as a 187 protein³¹. Variants of this system such as nickases, dead Cas9 binding DNA without cleavage, or 188 concomitant use of Cas9 inhibitors can further improve specificity or promote precise base 189 190 replacements³². Cas9 breaks can be repaired by homology-directed repair (HDR) and then promote precise integration of a template DNA flanked with adequate homology arms^{33,34}. These technologies are 191 in constant development and strongly expand the possibilities of manipulating DNA, with a huge 192 193 diversity of potential applications.

194 195

b. CRISPR edition in cell therapy

196 197 CRISPR tools recently allowed to insert a CD19-specific CAR in the T-cell receptor alpha (TCRA) locus, 198 improving both CAR expression, cytotoxicity, and persistence of functional CAR T cells in a preclinical model³⁵. Successful TCR gene replacement was then obtained both with an adeno-associated virus 199 (AAV), which favors HDR³⁶, and with a simple naked DNA template³⁷. The possibility to simultaneously 200 201 target several loci with CRISPR also opens the way for multiengineered universal off-the-shelf CAR T 202 cells (designed for tolerance by various recipients and limited graft-versus-host disease). Ren et al notably 203 succeeded in simultaneous CRISPR inactivation of TCR, B2M, and PDCD1 genes, generating universal 204 CAR T cells without human leukocyte antigen class I expression and capable of bypassing the PD-1 205 checkpoint inhibition³⁸.

The current challenge of CRISPR engineering in human T cells is to increase the proportion of successfully transformed cells, which is currently below that reached after viral transduction. Multiple attempts to improve HDR efficiency during CRISPR edition are thus currently tested^{39,40}. Cas9 variants with higher fidelity might also reduce off-target genomic lesions⁴¹. Such developments should more efficiently yield next-generation CAR T cells in a context where this therapy is increasingly used. Beyond the remaining challenges of mastering side effects and safety issues, it is also tempting to explore gene edition strategies for the therapeutic use of other types of human lymphoid cells and notably B cells.

214 215

216 4. Future immunotherapy strategies from the immunoglobulin/B-cell side

217 218 219

220

A. Gene therapy for in vivo mAb production (vectored immunotherapy)

a. <u>Vectored immunotherapy with viruses</u>

221 Although retro/lentiviruses have a known risk of oncogenesis⁴², AAVs currently stand as convenient 222 vectors for gene delivery, neither integrating into the host genome nor associating with any disease, and 223 successful therapy based on AAVs was demonstrated against hemophilia^{43,44}. Applications to mAb 224 225 delivery, termed vectored immunoprophylaxis, emerged for various infectious pathogens such as HIV⁴⁵ 226 (Figure 3) and proved efficient in mice against *Plasmodium falciparum* and Ebola virus and in monkeys against Simian immunodeficiency virus⁴⁶⁻⁴⁸. Vectored immunoprophylaxis might also treat tumors and 227 increased survival was notably obtained with AAV-encoded trastuzumab in mice carrying HER2⁺ 228 229 tumors⁴⁹.

230

The limited packaging capacity of AAVs has prompted to improve the design of cassettes coding for mAb chains. Addition of a self-processing P2A peptide allowed to encode both H and L chains using a monocistronic cassette⁵⁰. Several other formats of mAb-encoding cassettes were expressed from AAVs, but the frequent anti-AAV immune response constitutes a brake for clinical applications, together with antidrug antibodies targeting the therapeutic mAb. Despite such limitations, the AAV platform remains an interesting, vectored immunotherapy option.

b. <u>Naked DNA-encoded mAbs</u>

Naked DNA-encoded mAbs (DMAbs) stand as another platform for mAb in vivo delivery. It is relatively
 safe because naked DNA is neither infectious nor immunogenic by itself. Many studies thus used DMAbs
 to treat infection⁵¹⁻⁵⁷ or cancer^{58,59}. This strategy was initially limited by low expression, but delivery and
 expression have now been optimized⁶⁰.

244

238

239

245 Two mAb formats, either complete or restricted to the Fab, were compared by the DMAb strategy in the context of chikungunya infection, with the former providing the best immunity⁵³. Although this strategy 246 247 can rely on a single DNA fragment linking H and L chain sequences with a P2A site, simultaneous injection of several DMAbs was also shown possible^{51,52,54}. In both influenza and HIV infection, 248 combined DMAb yielded immunity^{54,52}. Muthumani et al highlighted another combination strategy by 249 250 simultaneously injecting a DNA vaccine encoding the CHIKV envelope and a DMAb that neutralizes the CHIVK⁵³. Patel et al, for their part, successfully used DMAb to produce a bispecific mAb that targets 2 251 252 proteins essential to *Pseudomonas aeruginosa* pathogenicity. Preliminary experiments in NHPs with 253 DMAb targeting the Zika virus suggested that this could be translatable to humans because it raised sufficient Ab levels for controlling viral load⁵⁶. DMAb targeting HIV also showed strong in vivo IgG 254 expression in NHP⁵². 255

256

Besides infections, this strategy is pertinent to oncology and demonstrated significant antitumor activity in vivo (being as effective as a conventional mAb) for controlling tumor growth^{58,59}, increasing CD8 Tcell infiltration, and decreasing the infiltration of T regulatory cells into tumors⁵⁸.

260

DMAb can thus be of interest for short- and medium-term treatment of various pathologies by rapidly and efficiently supporting the production of specific mAbs⁵⁵. Repeated DMAb injections are, however, needed when prolonged treatment is required. Safety issues also finally remain associated with the potential risk of oncogenic random genomic insertion.

266 c. <u>RNA injection: a safer alternative?</u>

267

268 As for CAR induction, in vivo mAb production has also motivated safe RNA-based approaches (with no risk of genomic insertion, oncogenic hit, or vector immunogenicity). Using lipid nanoparticles as carriers, 269 270 Pardi et al optimized the cytosolic transfer of the mRNA encoding H and L chains of an anti-HIV 271 neutralizing mAb⁶¹. A single intravenous dose of mRNA-lipid nanoparticles (LNPs) yielded in vivo mAb 272 expression at 170 µg/mL after 24 hours, and weekly administration made it possible to maintain a high 273 mAb concentration. This protected mice against challenge with an HIV derivative and showed that 274 mRNA-LNP coding for mAbs could replace mAb injection. In a recent and encouraging study, Kose et 275 al⁶² also showed that an mRNA encoding a chikungunya-neutralizing human mAb expressed after a 276 single intravenous injection of mRNA-LNPs decreased the viremia of mice challenged with the virus. Besides, it has also been shown that effective RNA-based approaches can be applied to cancer 277 immunotherapy^{63,64}. 278

Contrary to DNA injection, this strategy requires repeated administration to maintain a stable mAb level in vivo. Its transient efficacy (as for regular mAb treatment) can thus be a limitation for long-term treatments of chronic diseases, and more trials are still needed to ensure the absence of side effects. Despite this limitation, this drug format is significantly cheaper than proteins because the production of synthetic mRNA therapeutics⁶⁵ does not require expensive cell culture and purification systems. This is an important aspect, given the very high cost of mAb therapy.

285

286 B. Genome editing for in vivo mAb production

280

Genome editing technologies have strongly expanded the possibilities of manipulating DNA. When
 applied to Ab production, they allow more precise control via gene engineering of B-lineage cells.

Although in vivo cell modification therapies might be a future grail, ex vivo modification after cell sorting obviates the need for cell targeting⁶⁶. Another advantage is the possibility to analyze and characterize the modified cells before reintroducing them back into the host⁶⁷. In the context of mAb therapy, B-lineage cells isolated from peripheral blood or lymphoid organs are perfect targets, because they are the ultimate antibody-secreting cells⁶⁸. A system where B cells are isolated from peripheral blood, modified ex vivo for mAb secretion and injected back into the organism (**Figure 4**), would be an ideal therapeutic strategy with applications for both cancer and viral infection treatment⁶⁹.

298

Successful B-cell modification was first obtained using lentiviral transduction methods^{70–72}. Primary human hematopoietic cells, including B cells, were efficiently transduced with lentiviral vectors encoding anti-HIV broadly neutralizing Abs. Edited cells engrafted and persisted in blood and lymphoid tissues in vivo in humanized mice, efficiently secreting antiviral broadly neutralizing Abs⁷².

303

304 However, nonspecific lentiviral insertions could target regions essential for cell viability or function, compromising clinical applications⁶⁹. CRISPR/Cas9 site-specific cleavage can by contrast result in 305 precise insertion by HDR^{67,69}. Cas9, guide RNA (gRNA), and the repair template for HDR can be brought 306 into target cells as plasmids, mRNAs, or a ribonucleoprotein (RNP)^{66,69}. In primary human B cells, RNPs 307 seem to be highly efficient, whereas Cas9-encoding DNA and mRNA often lead to poor or no DNA 308 cleavage^{66,69}. To optimize HDR in cells at the S/G2 phases of the cell cycle^{34,73,74}, various B-cell expansion 309 mixtures were tested^{66,69,75}, and the optimal B-cell activation cocktail included CD40L, cytosine-310 phosphate-guanine (CpG), IL-2, IL-10, and IL-1575. 311

312

Efficient CRISPR/Cas9-mediated knockout in human B cells was obtained in several conditions^{66,69,75,76}. 313 Cheong et al⁷⁷ used lentiviral vectors carrying Cas9 and gRNA sequence. By using 2 gRNAs, 1 specific 314 for a region near S_{μ} and 1 near S_{ν} , they induced deletions and efficiently mimicked class switch 315 recombination in both mouse and human primary B cells. They also succeeded in generating Fab' 316 317 fragment-secreting hybridomas after deleting the Fc domain-coding region, with secretion at a level 318 comparable to the original complete immunoglobulin. This strategy would simplify the process of producing Fab' in vitro as proteins, which is currently based mainly on protease cleavage. Recently, an 319 320 integrase-defective lentiviral vector was also used to target precise insertion of an antibody cassette into 321 the *GAPDH* gene and yielded efficient expression in plasma cells⁷⁸.

323 Expressing transgenic immunoglobulins (ie, H2L2 polymers) in normal B cells in fact involves several 324 challenges: high expression, stoichiometric expression of both chains, and, if possible, disruption of 325 endogenous immunoglobulin genes to minimize the assembly of chimeric immunoglobulin (ie, randomly 326 mixing transgenic and endogenous immunoglobulin chains of unpredictable specificity). It is thus 327 desirable to design transgenic protocols also disrupting endogenous immunoglobulin production. HDR 328 knock-in (KI) at the immunoglobulin locus was thus explored using various strategies. The first successful immunoglobulin gene KI in B cells used an RNP/AAV combination^{69,75,79}. Reporter cassettes 329 were efficient inserted^{69,75}, and gene modification for secretion of a survival factor was achieved in human 330 331 PCs⁷⁵. Moffett et al⁷⁹ engineered the IgH locus to make cells secrete a mAb that bound the respiratory 332 syncytial virus (RSV). Their cassette was introduced upstream of the E_u enhancer and included a heavy 333 chain promoter, the light (L) chain, a long linker, and the variable region of the H chain. Such an sc 334 strategy both disrupted endogenous IgH chain production and forced an appropriate pairing of the 335 transgenic heavy (H) and L chain peptides. This cassette, followed by a site for splicing of the VDJ exon to the endogenous C_µ gene, thus encoded a complete (although sc) antibody. Electroporation with RNP 336 for cleavage was followed by incubation with AAV providing the KI cassette. This strategy led to 337 338 efficient expression of engineered immunoglobulin in primary human B cells, later differentiating into 339 PCs and secreting the engineered mAb.

340

341 Combination of RNP with double-strand or single-strand (ssDNA) DNA templates was also reported. In 342 mice, a KI cassette for an anti-RSV mAb provided as a double-strand DNA template successfully yielded anti-RSV immunity⁷⁹. Transferred cells were then able to differentiate in vivo into both long-lived PCs 343 and switched memory B cells. Greiner et al⁶⁶ inserted ssDNA templates into the H or L chain loci to 344 345 engineer B cells producing either mAbs or nanobodies that aimed at neutralizing tumor necrosis factor α. Hartweger et al⁸⁰ also used an ssDNA template to produce mAbs against HIV-1 and showed them to be 346 347 functional when produced either by engineered mouse or human B cells. Their strategy simultaneously 348 disrupted the κL chain in primary B cells using RNPs and expressed a transgenic H and L chains cassette, 349 inserted in the first IgH intron (downstream of JH). This cassette began with a stop cassette to interrupt 350 the transcription of the endogenous VDJ, followed by a VH promoter, a sequence encoding Igk, a P2A 351 cleavage site, and the VDJ region of the transgenic H chain. Splicing of a KI VDJ onto the endogenous constant region (as also cited for the work of Moffett et al⁷⁹) has the advantage to be compatible with 352 353 eventual class-switch recombination and production of the engineered mAb under various classes.

354

355 For all immunoglobulin gene engineering strategies presented thus far, a common issue is the low editing 356 efficiency, especially in primary B cells. A recent paper reported a method to increase editing yield, using nanoparticles and modifications of the HDR template⁸¹. Truncated Cas9 target sequences were added at 357 both ends of the repair template, allowing them to recruit Cas9. Using Cas9 variants coupled with nuclear 358 359 localization sequences, as a shuttle bringing the template to the genomic DNA, was also used, together 360 with poly-L-glutamic acid to stabilize RNP nanoparticles associated with HDR template. Altogether, these tricks enhanced editing efficiency in different cell types, especially when used jointly. In B cells, it 361 362 improved editing efficiency by fivefold. Poly-L-glutamic acid even permitted stabilized RNPs to resist 363 freeze-thaw cycles and lyophilization without losing efficiency. 364

Despite remaining difficulties and challenges, primary B-cell editing is obviously promising and worth 365 efforts. Modified B cells can differentiate into memory B cells and/or Ab-secreting PCs^{75,79}, and 366 successful differentiation of reinfused modified B cells was reported^{82,83}. Transferred PCs could eliminate 367 the need for periodic mAb injections⁶⁹, required for some current therapies because of limited persistence 368 369 in the organism⁷². In some patients with immune deficiency, it could replace vaccines to protect against 370 infections⁶⁹. Contrary to the fixed structure of mAbs, engineered B cells might also be eventually capable 371 of evolving into variants, notably through class switching, when appropriate insertion template is 372 used^{80,83,84}. Another possible evolution of an adoptive B-cell receptor in edited B lymphocytes might be 373 the entry into new rounds of Ag binding selection and in vivo affinity maturation^{79,84}. Such a feature 374 would be tremendously helpful for providing durable immunity against mutating antigens such as viruses 375 or cancer cells (evolving during chronic infection or reinfection or cancer relapse). Such adoptive 376 immunotherapy would then dynamically reformat humoral immunity on purpose, by redesigning B-cell 377 specificity while preserving their ability to evolve along successive immune challenges. 378

Among the methodologic breaks still needed before clinical applications, increasing the amount of mAb secreted by edited B cells is first. In most published models, mAb concentration rarely reached the level needed for immunity and rapidly declined⁷⁹. Ex vivo amplification of primary B cells and conditions for their commitment into either short or long-lived survival remain ill defined. Understanding how ex vivo

amplification could preserve or strengthen a long-lived commitment will need to be mastered for optimal
 B-cell engineering after optimized culture. Moreover, as only mouse models were used thus far,
 experimentation in NHP is required before clinical applications. By better mimicking the human patterns
 of viral infections or tumor progression, this will notably allow to estimate the number of cells required
 for a protective immunity and the best conditions for their successful graft.

388

Another major concern relates to the safety of gene edition in a lineage highly exposed to oncogenic 389 transformation and off-target mutations driven by the activation-induced deaminase activity^{85,79,80,84,86}. 390 Cas9 off-target mutations can be reduced by using nickase variants such as D10A⁸⁵ and then needing 2 391 392 adjacent on-target cleavage sites. This strongly reduces the risk of an off-target double-strand break. 393 Mutant Cas9 with reduced off-target activity are also reported⁸⁶. Safety issues for B-cell adoptive 394 immunotherapy could also partly be solved by efficient schemes for clearing edited cells in case of 395 undesired side effects. Efficient therapies are available for total B-cell or plasma cell deletion with anti-396 CD20 or anti-CD38 therapeutic mAbs. More specifically, suicide strategies such as inducible apoptosis by Cas12^{87,88} were validated in T-cell adoptive immunotherapy protocols and could be applied to edited B 397 398 cells.

399

400 Overall, despite these various efficiency and safety issues, there are already strong preliminary elements
 401 showing that adoptive B-cell immunotherapy is feasible and should soon take its part in the therapeutic
 402 arsenal, solving a number of unmet needs in human health.

403 404

405 Authors contribution statement: Conceptualization, M.Cogné, N.U, M.Cahen; Writing - original draft
406 preparation, M.Cogné, N.U, Y.D, M.Cahen; Writing - review and editing, M.Cogné, N.U, M.Cahen, C.S,
407 J.M; Supervision, M.Cogné; Funding acquisition, M.Cogné, C.S.

- 408
- 409 Conflict of interest disclosure: The authors have nothing to disclose.410

411 Acknowledgments: This work was supported by grant RF20180207070 from ARC Foundation for

412 Cancer Research to M. Cogné, and grant 18-CE18-0022-02 from French National Research Agency to M.

413 Cogné.

415

416 5. References

417 418

419 1. Garber K. Pursuit of tumor-infiltrating lymphocyte immunotherapy speeds up. *Nat. Biotechnol.*420 2019;37(9):969–971.

421 2. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute 422 lymphoid leukemia. *N. Engl. J. Med.* 2013;368(16):1509–1518.

423 3. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult 424 fibroblast cultures by defined factors. *Cell*. 2006;126(4):663–676.

425 4. Miyashita A, Fukushima S, Nakahara S, et al. Immunotherapy against Metastatic Melanoma with

Human iPS Cell-Derived Myeloid Cell Lines Producing Type I Interferons. *Cancer Immunol. Res.*2016;4(3):248–258.

428 5. Nabhan M, Pallardy M, Turbica I. Immunogenicity of Bioproducts: Cellular Models to Evaluate
429 the Impact of Therapeutic Antibody Aggregates. *Front. Immunol.* 2020;11:725.

Kijanka M, Dorresteijn B, Oliveira S, van Bergen en Henegouwen PMP. Nanobody-based cancer
therapy of solid tumors. *Nanomed.* 2015;10(1):161–174.

432 7. Wu L, Seung E, Xu L, et al. Trispecific antibodies enhance the therapeutic efficacy of tumor433 directed T cells through T cell receptor co-stimulation. *Nat. Cancer.* 2020;1(1):86–98.

434 8. Wiernik A, Foley B, Zhang B, et al. Targeting natural killer cells to acute myeloid leukemia in
435 vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition. *Clin. Cancer Res. Off. J.*436 *Am. Assoc. Cancer Res.* 2013;19(14):3844–3855.

437 9. Gauthier L, Morel A, Anceriz N, et al. Multifunctional Natural Killer Cell Engagers Targeting
438 NKp46 Trigger Protective Tumor Immunity. *Cell*. 2019;177(7):1701-1713.e16.

439 10. Davis ZB, Vallera DA, Miller JS, Felices M. Natural killer cells unleashed: Checkpoint receptor

blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy. *Semin. Immunol.*2017;31:64–75.

442 11. Xu L, Pegu A, Rao E, et al. Trispecific broadly neutralizing HIV antibodies mediate potent SHIV
443 protection in macaques. *Science*. 2017;358(6359):85–90.

444 12. Jackson HJ, Rafiq S, Brentjens RJ. Driving CAR T-cells forward. *Nat. Rev. Clin. Oncol.*445 2016;13(6):370–383.

446 13. Boice M, Salloum D, Mourcin F, et al. Loss of the HVEM Tumor Suppressor in Lymphoma and
447 Restoration by Modified CAR-T Cells. *Cell*. 2016;167(2):405-418.e13.

448 14. Wang W, Ma Y, Li J, et al. Specificity redirection by CAR with human VEGFR-1 affinity
449 endows T lymphocytes with tumor-killing ability and anti-angiogenic potency. *Gene Ther.*450 2013;20(10):970–978.

451 15. Chen Z-Y, He C-Y, Ehrhardt A, Kay MA. Minicircle DNA vectors devoid of bacterial DNA
452 result in persistent and high-level transgene expression in vivo. *Mol. Ther. J. Am. Soc. Gene Ther.*453 2003;8(3):495–500.

454 16. Vargas JE, Chicaybam L, Stein RT, et al. Retroviral vectors and transposons for stable gene 455 therapy: advances, current challenges and perspectives. *J. Transl. Med.* 2016;14:.

456 17. Magnani CF, Mezzanotte C, Cappuzzello C, et al. Preclinical Efficacy and Safety of CD19CAR
 457 Cytokine-Induced Killer Cells Transfected with Sleeping Beauty Transposon for the Treatment of Acute

458 Lymphoblastic Leukemia. *Hum. Gene Ther.* 2018;29(5):602–613.

459 18. Han J, Gao F, Geng S, et al. Minicircle DNA-Engineered CAR T Cells Suppressed Tumor
460 Growth in Mice. *Mol. Cancer Ther.* 2020;19(1):178–186.

461 19. Zhao Y, Zheng Z, Cohen CJ, et al. High-efficiency transfection of primary human and mouse T
462 lymphocytes using RNA electroporation. *Mol. Ther. J. Am. Soc. Gene Ther.* 2006;13(1):151–159.

463 20. Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: Mechanisms, 464 manifestations and management. *Blood Rev.* 2019;34:45–55.

465 21. Krug C, Wiesinger M, Abken H, et al. A GMP-compliant protocol to expand and transfect cancer
466 patient T cells with mRNA encoding a tumor-specific chimeric antigen receptor. *Cancer Immunol.*467 *Immunother. CII.* 2014;63(10):999–1008.

468 22. Smith TT, Stephan SB, Moffett HF, et al. In situ programming of leukaemia-specific T cells using
469 synthetic DNA nanocarriers. *Nat. Nanotechnol.* 2017;12(8):813–820.

470 23. Billingsley MM, Singh N, Ravikumar P, et al. Ionizable Lipid Nanoparticle-Mediated mRNA
471 Delivery for Human CAR T Cell Engineering. *Nano Lett.* 2020;20(3):1578–1589.

472 24. Ho BX, Loh SJH, Chan WK, Soh BS. In Vivo Genome Editing as a Therapeutic Approach. *Int. J.*473 *Mol. Sci.* 2018;19(9):.

- 474 25. Gaj T, Gersbach CA, Barbas CF. ZFN, TALEN, and CRISPR/Cas-based methods for genome 475 engineering. *Trends Biotechnol.* 2013;31(7):397–405.
- 476 26. Kim YG, Cha J, Chandrasegaran S. Hybrid restriction enzymes: zinc finger fusions to Fok I
 477 cleavage domain. *Proc. Natl. Acad. Sci. U. S. A.* 1996;93(3):1156–1160.
- 478 27. Chandrasegaran S, Carroll D. Origins of Programmable Nucleases for Genome Engineering. J.
 479 Mol. Biol. 2016;428(5 Pt B):963–989.
- 480 28. Qasim W, Zhan H, Samarasinghe S, et al. Molecular remission of infant B-ALL after infusion of
 481 universal TALEN gene-edited CAR T cells. *Sci. Transl. Med.* 2017;9(374):.
- 482 29. Barrangou R, Fremaux C, Deveau H, et al. CRISPR provides acquired resistance against viruses
 483 in prokaryotes. *Science*. 2007;315(5819):1709–1712.
- 484 30. Jinek M, Chylinski K, Fonfara I, et al. A programmable dual-RNA-guided DNA endonuclease in
 485 adaptive bacterial immunity. *Science*. 2012;337(6096):816–821.
- 486 31. Yin H, Kauffman KJ, Anderson DG. Delivery technologies for genome editing. *Nat. Rev. Drug*487 *Discov.* 2017;16(6):387–399.
- 488 32. Marino ND, Pinilla-Redondo R, Csörgő B, Bondy-Denomy J. Anti-CRISPR protein applications:
 489 natural brakes for CRISPR-Cas technologies. *Nat. Methods*. 2020;
- 490 33. Urnov FD, Rebar EJ, Holmes MC, Zhang HS, Gregory PD. Genome editing with engineered zinc
 491 finger nucleases. *Nat. Rev. Genet.* 2010;11(9):636–646.
- 492 34. Yamamoto Y, Gerbi SA. Making ends meet: targeted integration of DNA fragments by genome
 493 editing. *Chromosoma*. 2018;127(4):405–420.
- 494 35. Eyquem J, Mansilla-Soto J, Giavridis T, et al. Targeting a CAR to the TRAC locus with 495 CRISPR/Cas9 enhances tumour rejection. *Nature*. 2017;543(7643):113–117.
- 496 36. Moço PD, Aharony N, Kamen A. Adeno-Associated Viral Vectors for Homology-Directed
 497 Generation of CAR-T Cells. *Biotechnol. J.* 2020;15(1):e1900286.
- 498 37. Roth TL, Puig-Saus C, Yu R, et al. Reprogramming human T cell function and specificity with 499 non-viral genome targeting. *Nature*. 2018;559(7714):405–409.
- 38. Ren J, Liu X, Fang C, et al. Multiplex Genome Editing to Generate Universal CAR T Cells
 Resistant to PD1 Inhibition. *Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.* 2017;23(9):2255–2266.
- Tang X-D, Gao F, Liu M-J, et al. Methods for Enhancing Clustered Regularly Interspaced Short
 Palindromic Repeats/Cas9-Mediated Homology-Directed Repair Efficiency. *Front. Genet.* 2019;10:.
- 40. Aird EJ, Lovendahl KN, St Martin A, Harris RS, Gordon WR. Increasing Cas9-mediated
 homology-directed repair efficiency through covalent tethering of DNA repair template. *Commun. Biol.* 2018;1:54.
- 507 41. Kleinstiver BP, Prew MS, Tsai SQ, et al. Engineered CRISPR-Cas9 nucleases with altered PAM 508 specificities. *Nature*. 2015;523(7561):481–485.
- 509 42. Yi Y, Noh MJ, Lee KH. Current advances in retroviral gene therapy. *Curr. Gene Ther.* 510 2011;11(3):218–228.
- 43. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAVFactor IX and limitations imposed by the host immune response. *Nat. Med.* 2006;12(3):342–347.
- 513 44. Nathwani AC, Reiss UM, Tuddenham EGD, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. *N. Engl. J. Med.* 2014;371(21):1994–2004.
- 515 45. Balazs AB, Chen J, Hong CM, et al. Antibody-based protection against HIV infection by 516 vectored immunoprophylaxis. *Nature*. 2011;481(7379):81–84.
- 517 46. Deal C, Balazs AB, Espinosa DA, et al. Vectored antibody gene delivery protects against 518 Plasmodium falciparum sporozoite challenge in mice. *Proc. Natl. Acad. Sci. U. S. A.* 519 2014;111(34):12528–12532.
- 520 47. van Lieshout LP, Soule G, Sorensen D, et al. Intramuscular Adeno-Associated Virus–Mediated
- 521 Expression of Monoclonal Antibodies Provides 100% Protection Against Ebola Virus Infection in Mice.
 522 J. Infect. Dis. 2018;217(6):916–925.
- Martinez-Navio JM, Fuchs SP, Pantry SN, et al. Adeno-Associated Virus Delivery of Anti-HIV
 Monoclonal Antibodies Can Drive Long-Term Virologic Suppression. *Immunity*. 2019;50(3):567-575.e5.
- 49. Rothwell WT, Bell P, Richman LK, et al. Intrathecal Viral Vector Delivery of Trastuzumab
 Prevents or Inhibits Tumor Growth of Human HER2-Positive Xenografts in Mice. *Cancer Res.*2018;78(21):6171–6182.
- 528 50. Fang J, Qian J-J, Yi S, et al. Stable antibody expression at therapeutic levels using the 2A peptide.
 529 *Nat. Biotechnol.* 2005;23(5):584–590.
- 530 51. Flingai S, Plummer EM, Patel A, et al. Protection against dengue disease by synthetic nucleic 531 acid antibody prophylaxis/immunotherapy. *Sci. Rep.* 2015;5:12616.
- 532 52. Wise MC, Xu Z, Tello-Ruiz E, et al. In vivo delivery of synthetic DNA-encoded antibodies

- 533 induces broad HIV-1-neutralizing activity. J. Clin. Invest. 2020;130(2):827–837.
- 534 53. Muthumani K, Block P, Flingai S, et al. Rapid and Long-Term Immunity Elicited by DNA-535 Encoded Antibody Prophylaxis and DNA Vaccination Against Chikungunya Virus. *J. Infect. Dis.* 536 2016;214(3):369–378.
- 537 54. Elliott STC, Kallewaard NL, Benjamin E, et al. DMAb inoculation of synthetic cross reactive 538 antibodies protects against lethal influenza A and B infections. *NPJ Vaccines*. 2017;2:18.
- 539 55. Patel A, DiGiandomenico A, Keller AE, et al. An engineered bispecific DNA-encoded IgG
 540 antibody protects against Pseudomonas aeruginosa in a pneumonia challenge model. *Nat. Commun.*541 2017;8(1):637.
- 542 56. Esquivel RN, Patel A, Kudchodkar SB, et al. In Vivo Delivery of a DNA-Encoded Monoclonal
- 543 Antibody Protects Non-human Primates against Zika Virus. *Mol. Ther. J. Am. Soc. Gene Ther.* 544 2019;27(5):974–985.
- 545 57. Patel A, Park DH, Davis CW, et al. In Vivo Delivery of Synthetic Human DNA-Encoded 546 Monoclonal Antibodies Protect against Ebolavirus Infection in a Mouse Model. *Cell Rep.* 547 2018;25(7):1982-1993.e4.
- 548 58. Duperret EK, Trautz A, Stoltz R, et al. Synthetic DNA-Encoded Monoclonal Antibody Delivery 549 of Anti–CTLA-4 Antibodies Induces Tumor Shrinkage *In Vivo. Cancer Res.* 2018;canres;0008-550 5472.CAN-18-1429v2.
- 551 59. Muthumani K, Marnin L, Kudchodkar SB, et al. Novel prostate cancer immunotherapy with a 552 DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody. *Cancer Immunol.*
- 553 *Immunother*. 2017;66(12):1577–1588.
- 554 60. Tjelle TE, Corthay A, Lunde E, et al. Monoclonal antibodies produced by muscle after plasmid 555 injection and electroporation. *Mol. Ther. J. Am. Soc. Gene Ther.* 2004;9(3):328–336.
- 556 61. Pardi N, Secreto AJ, Shan X, et al. Administration of nucleoside-modified mRNA encoding 557 broadly neutralizing antibody protects humanized mice from HIV-1 challenge. *Nat. Commun.* 558 2017;8(1):14630.
- 559 62. Kose N, Fox JM, Sapparapu G, et al. A lipid-encapsulated mRNA encoding a potently 560 neutralizing human monoclonal antibody protects against chikungunya infection. *Sci. Immunol.* 561 2019;4(35):eaaw6647.
- 562 63. Stadler CR, Bähr-Mahmud H, Celik L, et al. Elimination of large tumors in mice by mRNA-563 encoded bispecific antibodies. *Nat. Med.* 2017;23(7):815–817.
- 64. Rybakova Y, Kowalski PS, Huang Y, et al. mRNA Delivery for Therapeutic Anti-HER2
 65. Antibody Expression In Vivo. *Mol. Ther. J. Am. Soc. Gene Ther.* 2019;27(8):1415–1423.
- 566 65. Pardi N, Hogan MJ, Weissman D. Recent advances in mRNA vaccine technology. *Curr. Opin.*567 *Immunol.* 2020;65:14–20.
- 568 66. Greiner V, Bou Puerto R, Liu S, et al. CRISPR-Mediated Editing of the B Cell Receptor in 569 Primary Human B Cells. *iScience*. 2019;12:369–378.
- 570 67. Barrangou R, Doudna JA. Applications of CRISPR technologies in research and beyond. *Nat.*571 *Biotechnol.* 2016;34(9):933–941.
- 572 68. Slifka MK, Antia R, Whitmire JK, Ahmed R. Humoral immunity due to long-lived plasma cells.
 573 *Immunity*. 1998;8(3):363–372.
- 574 69. Johnson MJ, Laoharawee K, Lahr WS, Webber BR, Moriarity BS. Engineering of Primary
 575 Human B cells with CRISPR/Cas9 Targeted Nuclease. *Sci. Rep.* 2018;8(1):12144.
- 576 70. Luo XM, Maarschalk E, O'Connell RM, et al. Engineering human hematopoietic stem/progenitor 577 cells to produce a broadly neutralizing anti-HIV antibody after in vitro maturation to human B 578 lymphocytes. *Blood*. 2009;113(7):1422–1431.
- 579 71. Fusil F, Calattini S, Amirache F, et al. A Lentiviral Vector Allowing Physiologically Regulated
 580 Membrane-anchored and Secreted Antibody Expression Depending on B-cell Maturation Status. *Mol.*581 *Ther.* 2015;23(11):1734–1747.
- 582 72. Kuhlmann A-S, Haworth KG, Barber-Axthelm IM, et al. Long-Term Persistence of Anti-HIV
 583 Broadly Neutralizing Antibody-Secreting Hematopoietic Cells in Humanized Mice. *Mol. Ther. J. Am.*584 Soc. Gene Ther. 2019;27(1):164–177.
- 585 73. Takata M, Sasaki MS, Sonoda E, et al. Homologous recombination and non-homologous end-586 joining pathways of DNA double-strand break repair have overlapping roles in the maintenance of 587 chromosomal integrity in vertebrate cells. *EMBO J.* 1998;17(18):5497–5508.
- 588 74. Heyer W-D, Ehmsen KT, Liu J. Regulation of homologous recombination in eukaryotes. *Annu.* 589 *Rev. Genet.* 2010;44:113–139.
- 590 75. Hung KL, Meitlis I, Hale M, et al. Engineering Protein-Secreting Plasma Cells by Homology-591 Directed Repair in Primary Human B Cells. *Mol. Ther.* 2018;26(2):456–467.

- 592 76. Wu C-AM, Roth TL, Baglaenko Y, et al. Genetic engineering in primary human B cells with 593 CRISPR-Cas9 ribonucleoproteins. *J. Immunol. Methods*. 2018;457:33–40.
- 594 77. Cheong T-C, Compagno M, Chiarle R. Editing of mouse and human immunoglobulin genes by 595 CRISPR-Cas9 system. *Nat. Commun.* 2016;7:10934.
- 596 78. Luo B, Zhan Y, Luo M, et al. Engineering of α-PD-1 antibody-expressing long-lived plasma cells
 597 by CRISPR/Cas9-mediated targeted gene integration. *Cell Death Dis.* 2020;11(11):973.
- 598 79. Moffett HF, Harms CK, Fitzpatrick KS, et al. B cells engineered to express pathogen-specific 599 antibodies protect against infection. *Sci. Immunol.* 2019;4(35):.
- 600 80. Hartweger H, McGuire AT, Horning M, et al. HIV-specific humoral immune responses by 601 CRISPR/Cas9-edited B cells. *J. Exp. Med.* 2019;216(6):1301–1310.
- 602 81. Nguyen DN, Roth TL, Li PJ, et al. Polymer-stabilized Cas9 nanoparticles and modified repair 603 templates increase genome editing efficiency. *Nat. Biotechnol.* 2020;38(1):44–49.
- 604 82. Wang X, Ray R, Kratochvil S, et al. Multiplexed CRISPR/CAS9-mediated engineering of 605 pre-clinical mouse models bearing native human B cell receptors. *EMBO J.* 2020;e105926:.
- 83. Nahmad AD, Raviv Y, Horovitz-Fried M, et al. Engineered B cells expressing an anti-HIV
 antibody enable memory retention, isotype switching and clonal expansion. *Nat. Commun.*2020;11(1):5851.
- 84. Voss JE, Gonzalez-Martin A, Andrabi R, et al. Reprogramming the antigen specificity of B cells
 using genome-editing technologies. *eLife*. 2019;8:.
- 611 85. Zhang X-H, Tee LY, Wang X-G, Huang Q-S, Yang S-H. Off-target Effects in CRISPR/Cas9-612 mediated Genome Engineering. *Mol. Ther. Nucleic Acids*. 2015;4:e264.
- 613 86. Vakulskas CA, Dever DP, Rettig GR, et al. A high-fidelity Cas9 mutant delivered as a 614 ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor 615 cells. *Nat. Med.* 2018;24(8):1216–1224.
- 616 87. Zhou X, Brenner MK. Improving the safety of T-Cell therapies using an inducible caspase-9 617 gene. *Exp. Hematol.* 2016;44(11):1013–1019.
- 618 88. Di Stasi A, Tey S-K, Dotti G, et al. Inducible apoptosis as a safety switch for adoptive cell
- 619 therapy. N. Engl. J. Med. 2011;365(18):1673–1683.

621 **Figures**

- 622 Figure 1. A timeline of the history of immunotherapy
- 623 Figure 2. New-generation mAb structures
- 624 Figure 3. In vivo production of mAb by additive gene therapy
- 625 Figure 4. A potential cycle of B cell-mediated therapies including an ex vivo genome edition step